Create Medicines raised $122 million to advance its in vivo CAR-T programs for cancers and autoimmune diseases, continuing a push toward therapies manufactured inside the body. The financing supports early clinical progression and expands the company’s pipeline built on mRNA–lipid nanoparticle delivery to reprogram T cells, NK cells, and myeloid cells. Create said it has dosed more than 50 patients across programs and recently initiated a Phase 1/2 trial for MT-304 targeting HER2-positive breast cancer and other HER2-expressing solid tumors. The approach aims to replace multi-step ex vivo cell manufacturing with a “one-day manufacturing process,” potentially improving speed and access. For the sector, the funding underscores that in vivo CAR-T is moving from concept to repeatable clinical execution, with investors rewarding platforms that can generate early efficacy and safety datasets at scale.